1. Home
  2. Companies
  3. BDX
  4. Material Events

Bcal Diagnostics (ASX:BDX) — Material Events

ASX:BDX · 19 articles in the last 12 months · 100% assessed

Click a band to jump to that tier

Major 1 article Significant 15 articles Notable 3 articles Not Assessed 0 articles
Major ≥90 Significant 75–89 Notable 50–74 Routine <50 Not assessed
Significant Score 75–89
15
BCAL Diagnostics Debuts BREASTESTplus™, Posts $7.24M Loss Amid US ExpansionMedium
BCAL Diagnostics launches BREASTESTplus™, reports $7.24M FY2025 loss, expands US operations
29 Aug 2025 ·Annual Report ·85
BCAL Diagnostics Advances National Cancer Test Rollout and Medicare BidMedium
BCAL Diagnostics launches national Avantect tests, advances BREASTESTplus 2.0, seeks Medicare reimbursement
22 Apr 2026 ·Quarterly Activities Report and Appendix 4C ·85
BCAL Diagnostics Integrates Early Cancer Tests into GP Software and Launches Telehealth ServiceMedium
BCAL Diagnostics expands early cancer test access via GP software, telehealth launch, and new clinic
19 May 2026 ·Corporate Update ·85
BCAL Secures Exclusive Rights for Early Pancreatic and Ovarian Cancer Blood Tests in AustraliaMedium
BCAL partners with ClearNote to launch early pancreatic and ovarian cancer blood tests in Australia and NZ
18 Sept 2025 ·ASX Announcement ·85
BCAL Diagnostics Sees Strong Early Demand for Avantect Cancer TestsMedium
BCAL Diagnostics launches Avantect cancer tests with strong early demand and advances BREASTESTplus
5 Feb 2026 ·Shareholder Update ·80
BCAL Diagnostics Launches Avantect Cancer Tests, Expands BREASTESTplus ReachMedium
BCAL Diagnostics launches Avantect cancer tests in Australia, expands BREASTESTplus data, secures $10M convertible note
21 Jan 2026 ·Quarterly Activities Report and Appendix 4C ·80
BCAL Diagnostics Accelerates Cancer Test Rollout with $10M Funding BoostMedium
BCAL Diagnostics expands cancer test partnerships, grows BREASTESTplus sales, and secures $10M funding facility
31 Oct 2025 ·Quarterly Activities Report and Appendix 4C ·80
BCAL Diagnostics Names Anne-Louise Arnett as CEO to Drive Commercial ExpansionMedium
BCAL Diagnostics names Anne-Louise Arnett as new CEO to drive commercial growth
11 May 2026 ·Executive Appointment ·80
BCAL Diagnostics Secures $10M Convertible Note to Fuel Cancer Test RolloutMedium
BCAL Diagnostics secures $10M convertible note facility to fund cancer detection commercialisation
20 Oct 2025 ·Capital Raising ·75
BCAL Diagnostics Unveils Blood Test Targeting Local Breast Cancer RecurrenceMedium
BCAL develops blood test BREASTEST Monitor for detecting local breast cancer recurrence
18 June 2026 ·Product Development Update ·75
BCAL Diagnostics Secures $10M Convertible Note Facility to Boost Cancer Test RolloutMedium
BCAL Diagnostics launches $10M Convertible Note facility with $5M committed
20 Oct 2025 ·Capital Raising ·75
BCAL Diagnostics Accelerates BREASTEST plus Rollout with Strategic Cancer Care PartnershipMedium
BCAL Diagnostics launches BREASTEST plus commercially with strong early uptake and strategic partnership
30 July 2025 ·Appendix 4C Quarterly Activities Report ·75
BCAL Expands BREASTEST plus™ Access via Sonic’s 93 Sydney CentresMedium
BCAL partners with Sonic Healthcare to expand BREASTEST plus™ access across Sydney
27 Aug 2025 ·Commercial Partnership Announcement ·75
BCAL Diagnostics Accelerates National Rollout of Avantect Cancer Blood TestsMedium
BCAL Diagnostics expands national rollout of Avantect pancreatic and ovarian cancer blood tests
26 Mar 2026 ·ASX Announcement ·75
BCAL Takes 10% Stake in Genetic Signatures to Broaden Diagnostics ReachMedium
BCAL acquires 10.2% stake in Genetic Signatures to expand diagnostics portfolio
2 July 2026 ·Strategic Investment Announcement ·75
Not Assessed Low Score, or missing data
0

No articles in this tier for the last 12 months.